Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
- PMID: 3560161
- DOI: 10.1021/jm00387a014
Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
Abstract
The synthesis, physicochemical properties, and antitumor activity of a series of N-[2-(dialkylamino)alkyl]-acridine-4-carboxamides are reported. The compounds bind to DNA by intercalation, but exist under physiological conditions as monocations due to the weakly basic acridine chromophore (pKa = 3.5-4.5). The acridine-4-carboxamides show very broad structure-activity relationships (SAR) for antileukemic activity, with substituents at nearly all acridine positions proving acceptable. The compounds also show remarkable activity against the Lewis lung solid tumor in vivo, with several analogues capable of effecting 100% cures of the advanced disease. The broad SAR and high solid-tumor activity of the 9-acridine-4-carboxamides imply they should be considered as a completely new class of antitumor agent.
Similar articles
-
Potential antitumor agents. 49. 5-substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity.J Med Chem. 1987 Apr;30(4):658-63. doi: 10.1021/jm00387a013. J Med Chem. 1987. PMID: 3560160
-
Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.J Med Chem. 1994 Mar 4;37(5):593-7. doi: 10.1021/jm00031a008. J Med Chem. 1994. PMID: 8126699
-
Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents.J Med Chem. 1988 Apr;31(4):774-9. doi: 10.1021/jm00399a015. J Med Chem. 1988. PMID: 3351855
-
Intercalators as anticancer drugs.Curr Pharm Des. 2001 Nov;7(17):1745-80. doi: 10.2174/1381612013397113. Curr Pharm Des. 2001. PMID: 11562309 Review.
-
Dihydroxyanthraquinone and related bis(substituted) aminoanthraquinones: a novel class of antitumor agents.Pharmacol Ther. 1983;22(2):199-214. doi: 10.1016/0163-7258(83)90004-9. Pharmacol Ther. 1983. PMID: 6361801 Review. No abstract available.
Cited by
-
Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.Clin Cancer Res. 2008 Dec 15;14(24):8184-90. doi: 10.1158/1078-0432.CCR-08-1324. Clin Cancer Res. 2008. PMID: 19088034 Free PMC article.
-
Dual Inhibitors Against Topoisomerases and Histone Deacetylases.J Cancer Prev. 2015 Jun;20(2):85-91. doi: 10.15430/JCP.2015.20.2.85. J Cancer Prev. 2015. PMID: 26151040 Free PMC article. Review.
-
A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)(2).Nucleic Acids Res. 2000 Nov 1;28(21):4244-53. doi: 10.1093/nar/28.21.4244. Nucleic Acids Res. 2000. PMID: 11058124 Free PMC article.
-
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.Drug Metab Dispos. 2013 Jan;41(1):24-9. doi: 10.1124/dmd.112.048546. Epub 2012 Sep 20. Drug Metab Dispos. 2013. PMID: 22996261 Free PMC article.
-
Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.Cancer Chemother Pharmacol. 1992;29(6):439-44. doi: 10.1007/BF00684844. Cancer Chemother Pharmacol. 1992. PMID: 1568286
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous